Meld Criteria in the Transplant Waiting List: Impact on Mortality Overall and by Diagnostic Groups
Main Author: | |
---|---|
Publication Date: | 2022 |
Other Authors: | , |
Format: | Article |
Language: | eng por spa |
Source: | Brazilian Journal of Transplantation |
Download full: | https://bjt.emnuvens.com.br/revista/article/view/454 |
Summary: | The modification of liver graft allocation for selection by severity criteria based on the Model for End-Stage Liver Disease (Meld) has not yet been properly analyzed in Brazil regarding the distribution of indications for transplant and mortality among enrolled patients. In a context of low organ donation and procurement, this assessment is relevant. Objective: To compare mortality on the liver transplant waiting list in Brazil before and after the adoption of Meld score as a criterion for allocation on the waiting list: overall, by diagnostic group, and by Meld range at enrollment. Methods: We retrospectively studied 899 patients (median age = 52.8 years, body mass index, BMI = 25.2 and Meld = 18) divided into the pre- (n = 320, 35.6%) and post-Meld (n = 579, 64.4%) periods and into groups: 1 (n = 480, 53.4%): ethanolic, cryptogenic and autoimmune cirrhosis; 2 (n = 80, 8.9%): biliary diseases; 3 (n = 93, 10.3%): metabolic and other diseases; and 4 (n = 246, 27.4%): post-viral B and C cirrhosis. Special scoring was assigned to 19.5% of patients, according to legislation criteria. The sample was also divided by Meld ranges at enrollment (< 18; 18–24; and > 24). Waitlist mortalities of the pre- and post-Meld groups were compared in the total sample, in each diagnostic group, and in each Meld range. Results: The incidence of referrals to transplantation was different in the pre- and post-Meld eras (p = 0.049), increasing in group 3 (from 8.1 to 11.6%) and decreasing in group 4 (from 32.5 to 24.5%). Of the enrollees, 32.9% died before transplantation. Mean Meld increased from 16 to 20 (p < 0.001), and mean time between enrollment and outcome (transplant or death) decreased from 102 days to 58 (p = 0.028). Waiting list mortality dropped from 105.7% (patient-years) to 54.9% in the post-Meld group (p = 0.001). There was a reduction from 104.2% (patientyears) to 51.1% (p = 0.034) in group 1, and the proportion fell from 160.3% (patient-years) to 52% (p = 0.019) in group 2. On the other hand, there was no statistically significant variation in the groups 3 and 4. In Meld range 1 (< 18), mortality ranged from 87.2% per patient-year to 24.1% per patientyear (p = 0.005). In Meld range 2 (18–24), it ranged from 109.8 to 72.4% per patient-year (p = 0.019). In the Meld > 24 range, there was no significant change in waitlist mortality. Finally, survival at 1, 3 and 12 months after transplantation did not vary significantly between the pre-Meld and postMeld era. Conclusion: Comparing the pre- and post-Meld groups, patients were enrolled when they were most severely ill, and there was a reduction in mean time on the list for the outcome and a decrease in waiting list mortality with no change in post-transplant survival. Diagnosis groups 1 and 2 have benefited. In addition, the decrease in waiting list mortality was observed among patients with Meld < 24 at the time of enrollment. This reduction was not observed in the group of patients with Meld > 24 |
id |
ABTO_c2730225d162c9cf1fd9dbd14f8b1ee5 |
---|---|
oai_identifier_str |
oai:ojs3.emnuvens.com.br:article/454 |
network_acronym_str |
ABTO |
network_name_str |
Brazilian Journal of Transplantation |
repository_id_str |
|
spelling |
Meld Criteria in the Transplant Waiting List: Impact on Mortality Overall and by Diagnostic GroupsMeld Criteria in the Transplant Waiting List: Impact on Mortality Overall and by Diagnostic GroupsCritério Meld na Fila de Transplantes: Impacto na Mortalidade Geral e por Grupos DiagnósticosTransplante de ÓrgãosTransplante de FígadoFígadoOrgan TransplantationLiver TransplantationLiverTransplante de ÓrganosTransplante de HígadoHígadoThe modification of liver graft allocation for selection by severity criteria based on the Model for End-Stage Liver Disease (Meld) has not yet been properly analyzed in Brazil regarding the distribution of indications for transplant and mortality among enrolled patients. In a context of low organ donation and procurement, this assessment is relevant. Objective: To compare mortality on the liver transplant waiting list in Brazil before and after the adoption of Meld score as a criterion for allocation on the waiting list: overall, by diagnostic group, and by Meld range at enrollment. Methods: We retrospectively studied 899 patients (median age = 52.8 years, body mass index, BMI = 25.2 and Meld = 18) divided into the pre- (n = 320, 35.6%) and post-Meld (n = 579, 64.4%) periods and into groups: 1 (n = 480, 53.4%): ethanolic, cryptogenic and autoimmune cirrhosis; 2 (n = 80, 8.9%): biliary diseases; 3 (n = 93, 10.3%): metabolic and other diseases; and 4 (n = 246, 27.4%): post-viral B and C cirrhosis. Special scoring was assigned to 19.5% of patients, according to legislation criteria. The sample was also divided by Meld ranges at enrollment (< 18; 18–24; and > 24). Waitlist mortalities of the pre- and post-Meld groups were compared in the total sample, in each diagnostic group, and in each Meld range. Results: The incidence of referrals to transplantation was different in the pre- and post-Meld eras (p = 0.049), increasing in group 3 (from 8.1 to 11.6%) and decreasing in group 4 (from 32.5 to 24.5%). Of the enrollees, 32.9% died before transplantation. Mean Meld increased from 16 to 20 (p < 0.001), and mean time between enrollment and outcome (transplant or death) decreased from 102 days to 58 (p = 0.028). Waiting list mortality dropped from 105.7% (patient-years) to 54.9% in the post-Meld group (p = 0.001). There was a reduction from 104.2% (patientyears) to 51.1% (p = 0.034) in group 1, and the proportion fell from 160.3% (patient-years) to 52% (p = 0.019) in group 2. On the other hand, there was no statistically significant variation in the groups 3 and 4. In Meld range 1 (< 18), mortality ranged from 87.2% per patient-year to 24.1% per patientyear (p = 0.005). In Meld range 2 (18–24), it ranged from 109.8 to 72.4% per patient-year (p = 0.019). In the Meld > 24 range, there was no significant change in waitlist mortality. Finally, survival at 1, 3 and 12 months after transplantation did not vary significantly between the pre-Meld and postMeld era. Conclusion: Comparing the pre- and post-Meld groups, patients were enrolled when they were most severely ill, and there was a reduction in mean time on the list for the outcome and a decrease in waiting list mortality with no change in post-transplant survival. Diagnosis groups 1 and 2 have benefited. In addition, the decrease in waiting list mortality was observed among patients with Meld < 24 at the time of enrollment. This reduction was not observed in the group of patients with Meld > 24La modificación de la ubicación de injertos hepáticos para selección por el criterio de gravedad basado en el model for end-stage liver disease (Meld) aún no fue debidamente analizada en Brasil con respecto a la distribución de las indicaciones al transplante y a la mortalidad entre los pacientes inscritos. En un contexto de baja donación y captación de órganos, esta evaluación es relevante. Objetivo: Comparar la mortalidad en la lista de espera de transplante hepático en Brasil antes y después de la adopción del score Meld como criterio de ubicación en la fila: general, por grupo diagnóstico y por rango de Meld a la inscripción. Métodos: Fueron estudiados, retrospectivamente, 899 pacientes (medianas de edad=52,8 años, índice de masa corpórea=25,2 y Meld=18) divididos en los períodos pre (n=320, 35,6%) y post-Meld (n=579, 64,4%) y en grupos: 1 (n=480, 53,4%): cirrosis etanólica, criptogénica y autoinmune; 2 (n=80, 8,9%): enfermedades biliares; 3 (n=93, 10,3%): enfermedades metabólicas y otros; y 4 (n=246, 27,4%): cirrosis postviral B y C. Puntuación especial fue atribuida al 19,5% de los pacientes, de acuerdo con criterios de la legislación. La muestra fue dividida también por rangos de Meld a la inscripción (<18; 18-24; y >24). Las mortalidades de la lista de espera de los grupos pre y post-Meld fueron comparadas en la muestra total, en cada grupo diagnóstico y en cada rango de Meld. Resultados: La incidencia de indicaciones al transplante fue diferente en las eras pre y post-Meld (p=0,049), aumentando en el grupo 3 (de 8,1 para 11,6%) y reduciéndose en el grupo 4 (de 32,5 para 24,5%). De los inscritos, 32,9% fallecieron antes del transplante. El Meld promedio aumentó de 16 para 20 (p<0,001), y el tiempo promedio entre la inscripción y el desenlace (transplante o fallecimiento) disminuyó de 102 días para 58 (p=0,028). La mortalidad en la lista de espera cayó de 105,7% (pacientes-año) para 54,9% en el grupo post-Meld (p=0,001). En el grupo 1 hubo una reducción de 104,2% (pacientes-año) para 51,1% (p=0,034), y en el grupo 2 la proporción cayó de 160,3% (pacientes-año) para 52% (p=0,019). Ya en los grupos 3 y 4 no hubo variación estadísticamente significativa. En el rango de Meld 1 (<18), la mortalidad varió de 87,2% por paciente-año a 24,1% por paciente-año (p=0,005). En el rango 2 (18-24), varió de 109,8 a 72,4% por paciente-año (p=0,019). En el rango de Meld>24, no hubo cambio significativo en la mortalidad en la lista de espera. Por fin, la sobrevida en uno, tres y 12 meses después del transplante no varió significativamente entre la era preMeld y post-Meld. Conclusión: Comparándose los grupos pre y post-Meld, los pacientes fueron inscritos cuando estaban más graves, y hubo reducción del tiempo promedio de evolución en la lista para el desenlace y disminución de la mortalidad en la lista de espera sin modificación de la sobrevida postransplante. Los grupos diagnósticos 1 y 2 fueron beneficiados. Además de esto, la disminución de la mortalidad en la lista de espera fue observada entre los pacientes con Meld<24 en el momento de la inscripción. Esta reducción no fue observada en el grupo de pacientes con Meld>24.A modificação da alocação de enxertos hepáticos para seleção pelo critério de gravidade baseado no model for end-stage liver disease (Meld) ainda não foi devidamente analisada no Brasil quanto à distribuição das indicações ao transplante e à mortalidade entre os pacientes inscritos. Em um contexto de baixa doação e captação de órgãos, essa avaliação é relevante. Objetivo: Comparar a mortalidade na lista de espera de transplante hepático no Brasil antes e depois da adoção do escore Meld como critério de alocação na fila: geral, por grupo diagnóstico e por faixa de Meld à inscrição. Métodos: Foram estudados, retrospectivamente, 899 pacientes (medianas de idade=52,8 anos, índice de massa corpórea=25,2 e Meld=18) divididos nos períodos pré (n=320, 35,6%) e pós-Meld (n=579, 64,4%) e em grupos: 1 (n=480, 53,4%): cirrose etanólica, criptogênica e autoimune; 2 (n=80, 8,9%): doenças biliares; 3 (n=93, 10,3%): doenças metabólicas e outros; e 4 (n=246, 27,4%): cirroses pós-viral B e C. Pontuação especial foi atribuída a 19,5% dos pacientes, de acordo com critérios da legislação. A amostra foi dividida também por faixas de Meld à inscrição (<18; 18-24; e >24). As mortalidades da lista de espera dos grupos pré e pós-Meld foram comparadas na amostra total, em cada grupo diagnóstico e em cada faixa de Meld. Resultados: A incidência de indicações ao transplante foi diferente nas eras pré e pós-Meld (p=0,049), aumentando no grupo 3 (de 8,1 para 11,6%) e reduzindo-se no grupo 4 (de 32,5 para 24,5%). Dos inscritos, 32,9% faleceram antes do transplante. O Meld médio aumentou de 16 para 20 (p<0,001), e o tempo médio entre a inscrição e o desfecho (transplante ou óbito) diminuiu de 102 dias para 58 (p=0,028). A mortalidade na lista de espera caiu de 105,7% (pacientes-ano) para 54,9% no grupo pósMeld (p=0,001). No grupo 1 houve redução de 104,2% (pacientes-ano) para 51,1% (p=0,034), e no grupo 2 a proporção caiu de 160,3% (pacientes-ano) para 52% (p=0,019). Já nos grupos 3 e 4 não houve variação estatisticamente significativa. Na faixa de Meld 1 (<18), a mortalidade variou de 87,2% por paciente-ano a 24,1% por paciente-ano (p=0,005). Na faixa 2 (18-24), variou de 109,8 a 72,4% por paciente-ano (p=0,019). Na faixa de Meld>24, não houve mudança significativa na mortalidade na lista de espera. Por fim, a sobrevida em um, três e 12 meses após o transplante não variou significativamente entre a era pré-Meld e pós-Meld. Conclusão: Comparando-se os grupos pré e pós-Meld, os pacientes foram inscritos quando estavam mais graves, e houve redução do tempo médio de evolução na lista para o desfecho e diminuição da mortalidade na lista de espera sem alteração da sobrevida pós-transplante. Os grupos diagnósticos 1 e 2 foram beneficiados. Além disso, a diminuição da mortalidade na lista de espera foi observada entre os pacientes com Meld<24 no momento da inscrição. Essa redução não foi observada no grupo de pacientes com Meld>24.Associação Brasileira de Transplante de Órgãos (ABTO)2022-06-15info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfapplication/pdfhttps://bjt.emnuvens.com.br/revista/article/view/454Brazilian Journal of Transplantation; Vol. 25 No. 2 (2022)Brazilian Journal of Transplantation; v. 25 n. 2 (2022)2764-1589reponame:Brazilian Journal of Transplantationinstname:Associação Brasileira de Transplante de Órgãos (ABTO)instacron:ABTOengporspahttps://bjt.emnuvens.com.br/revista/article/view/454/458https://bjt.emnuvens.com.br/revista/article/view/454/459https://bjt.emnuvens.com.br/revista/article/view/454/460Copyright (c) 2022 Caio Ribeiro Melki, João Lucas Ribeiro e Fernandes, Agnaldo Soares Limainfo:eu-repo/semantics/openAccessRibeiro Melki, CaioRibeiro e Fernandes, João LucasSoares Lima, Agnaldo2022-07-21T10:49:59Zoai:ojs3.emnuvens.com.br:article/454Revistahttps://bjt.emnuvens.com.br/revistaONGhttps://bjt.emnuvens.com.br/revista/oaibjt@abto.org.brhttps://doi.org/10.53855/2764-15892764-1589opendoar:2022-07-21T10:49:59Brazilian Journal of Transplantation - Associação Brasileira de Transplante de Órgãos (ABTO)false |
dc.title.none.fl_str_mv |
Meld Criteria in the Transplant Waiting List: Impact on Mortality Overall and by Diagnostic Groups Meld Criteria in the Transplant Waiting List: Impact on Mortality Overall and by Diagnostic Groups Critério Meld na Fila de Transplantes: Impacto na Mortalidade Geral e por Grupos Diagnósticos |
title |
Meld Criteria in the Transplant Waiting List: Impact on Mortality Overall and by Diagnostic Groups |
spellingShingle |
Meld Criteria in the Transplant Waiting List: Impact on Mortality Overall and by Diagnostic Groups Ribeiro Melki, Caio Transplante de Órgãos Transplante de Fígado Fígado Organ Transplantation Liver Transplantation Liver Transplante de Órganos Transplante de Hígado Hígado |
title_short |
Meld Criteria in the Transplant Waiting List: Impact on Mortality Overall and by Diagnostic Groups |
title_full |
Meld Criteria in the Transplant Waiting List: Impact on Mortality Overall and by Diagnostic Groups |
title_fullStr |
Meld Criteria in the Transplant Waiting List: Impact on Mortality Overall and by Diagnostic Groups |
title_full_unstemmed |
Meld Criteria in the Transplant Waiting List: Impact on Mortality Overall and by Diagnostic Groups |
title_sort |
Meld Criteria in the Transplant Waiting List: Impact on Mortality Overall and by Diagnostic Groups |
author |
Ribeiro Melki, Caio |
author_facet |
Ribeiro Melki, Caio Ribeiro e Fernandes, João Lucas Soares Lima, Agnaldo |
author_role |
author |
author2 |
Ribeiro e Fernandes, João Lucas Soares Lima, Agnaldo |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Ribeiro Melki, Caio Ribeiro e Fernandes, João Lucas Soares Lima, Agnaldo |
dc.subject.por.fl_str_mv |
Transplante de Órgãos Transplante de Fígado Fígado Organ Transplantation Liver Transplantation Liver Transplante de Órganos Transplante de Hígado Hígado |
topic |
Transplante de Órgãos Transplante de Fígado Fígado Organ Transplantation Liver Transplantation Liver Transplante de Órganos Transplante de Hígado Hígado |
description |
The modification of liver graft allocation for selection by severity criteria based on the Model for End-Stage Liver Disease (Meld) has not yet been properly analyzed in Brazil regarding the distribution of indications for transplant and mortality among enrolled patients. In a context of low organ donation and procurement, this assessment is relevant. Objective: To compare mortality on the liver transplant waiting list in Brazil before and after the adoption of Meld score as a criterion for allocation on the waiting list: overall, by diagnostic group, and by Meld range at enrollment. Methods: We retrospectively studied 899 patients (median age = 52.8 years, body mass index, BMI = 25.2 and Meld = 18) divided into the pre- (n = 320, 35.6%) and post-Meld (n = 579, 64.4%) periods and into groups: 1 (n = 480, 53.4%): ethanolic, cryptogenic and autoimmune cirrhosis; 2 (n = 80, 8.9%): biliary diseases; 3 (n = 93, 10.3%): metabolic and other diseases; and 4 (n = 246, 27.4%): post-viral B and C cirrhosis. Special scoring was assigned to 19.5% of patients, according to legislation criteria. The sample was also divided by Meld ranges at enrollment (< 18; 18–24; and > 24). Waitlist mortalities of the pre- and post-Meld groups were compared in the total sample, in each diagnostic group, and in each Meld range. Results: The incidence of referrals to transplantation was different in the pre- and post-Meld eras (p = 0.049), increasing in group 3 (from 8.1 to 11.6%) and decreasing in group 4 (from 32.5 to 24.5%). Of the enrollees, 32.9% died before transplantation. Mean Meld increased from 16 to 20 (p < 0.001), and mean time between enrollment and outcome (transplant or death) decreased from 102 days to 58 (p = 0.028). Waiting list mortality dropped from 105.7% (patient-years) to 54.9% in the post-Meld group (p = 0.001). There was a reduction from 104.2% (patientyears) to 51.1% (p = 0.034) in group 1, and the proportion fell from 160.3% (patient-years) to 52% (p = 0.019) in group 2. On the other hand, there was no statistically significant variation in the groups 3 and 4. In Meld range 1 (< 18), mortality ranged from 87.2% per patient-year to 24.1% per patientyear (p = 0.005). In Meld range 2 (18–24), it ranged from 109.8 to 72.4% per patient-year (p = 0.019). In the Meld > 24 range, there was no significant change in waitlist mortality. Finally, survival at 1, 3 and 12 months after transplantation did not vary significantly between the pre-Meld and postMeld era. Conclusion: Comparing the pre- and post-Meld groups, patients were enrolled when they were most severely ill, and there was a reduction in mean time on the list for the outcome and a decrease in waiting list mortality with no change in post-transplant survival. Diagnosis groups 1 and 2 have benefited. In addition, the decrease in waiting list mortality was observed among patients with Meld < 24 at the time of enrollment. This reduction was not observed in the group of patients with Meld > 24 |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-06-15 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://bjt.emnuvens.com.br/revista/article/view/454 |
url |
https://bjt.emnuvens.com.br/revista/article/view/454 |
dc.language.iso.fl_str_mv |
eng por spa |
language |
eng por spa |
dc.relation.none.fl_str_mv |
https://bjt.emnuvens.com.br/revista/article/view/454/458 https://bjt.emnuvens.com.br/revista/article/view/454/459 https://bjt.emnuvens.com.br/revista/article/view/454/460 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2022 Caio Ribeiro Melki, João Lucas Ribeiro e Fernandes, Agnaldo Soares Lima info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2022 Caio Ribeiro Melki, João Lucas Ribeiro e Fernandes, Agnaldo Soares Lima |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Associação Brasileira de Transplante de Órgãos (ABTO) |
publisher.none.fl_str_mv |
Associação Brasileira de Transplante de Órgãos (ABTO) |
dc.source.none.fl_str_mv |
Brazilian Journal of Transplantation; Vol. 25 No. 2 (2022) Brazilian Journal of Transplantation; v. 25 n. 2 (2022) 2764-1589 reponame:Brazilian Journal of Transplantation instname:Associação Brasileira de Transplante de Órgãos (ABTO) instacron:ABTO |
instname_str |
Associação Brasileira de Transplante de Órgãos (ABTO) |
instacron_str |
ABTO |
institution |
ABTO |
reponame_str |
Brazilian Journal of Transplantation |
collection |
Brazilian Journal of Transplantation |
repository.name.fl_str_mv |
Brazilian Journal of Transplantation - Associação Brasileira de Transplante de Órgãos (ABTO) |
repository.mail.fl_str_mv |
bjt@abto.org.br |
_version_ |
1836111235144220672 |